Reset filter
Palavras-chave
AML ×
Mostrar mais Palavras-chave
Índice
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

269 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

International Standard for Diagnosis and Management of AML - International Concepts in AML H. Döhner et. al. 2010

- 20.09.21 - 1 Formulário, 7 Grupos de itens, 154 Elementos de dados, 1 Idioma
Grupos de itens: Table 2. Expression of cell-surface and cytoplasmic markers for the diagnosis of acute myeloid leukemia and mixed phenotype acute leukemia, Table 3. Test/procedures in the initial work-up of a patient with AML, Table 4. Standardized reporting for correlation of cytogenetic and molecular genetic data in AML with clinical data, Table 5. Response criteria in AML, Lab Panel, Additional text-derived items - e.g. Clinical findings, Clinical Parameters
ODM form derived from H. Döhner et. al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. 2010; Blood: 115 (3) Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/?term=19880497

Eligibility NCT00915252 Acute Myeloid Leukemia - Eligibility

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 24 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00915252

Eligibility DRKS00000733 NCT00867672 Acute Myeloid Leukemia - Eligibility

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 19 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00867672

Eligibility DRKS00006115 NCT00822393 Acute Myeloid Leukemia - Eligibility

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 24 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00822393

Eligibility DRKS00003750 NCT00804856 Leukemia, Myeloid, Acute - Eligibility

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 27 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00804856

1. induction therapy adverse events AML NCT00180102

- 20.09.21 - 1 Formulário, 49 Grupos de itens, 239 Elementos de dados, 2 Idiomas
Grupos de itens: General information, allergic reaction, Hämoglobin, Leukocytes, Neutrophils, Platelets, Arrhythmias, Cardiac ischemia/infarction, Hypertension, Hypotension, Left ventricular systolic dysfunction, Pericarditis, Pulmonary Hypertension, DIC, Fibrinogen, Fever (Neutrophils > 1,0 GPt/l), Neutropenic fever, Rash/desquamation, Pancreas endocrine, Diarrhea, Dysphagia/Esophagitis/Gastritis/Ileus, Enteritis, Mukositis/Stomatitis, Nausea and vomiting, Hemorrhage, Pankreatitis, Infection, Alkaline Phosphatase, ALAT, GPT, ASAT, GOT, Bilirubin, Creatinine, GGT, Ataxia, Motor neuropathy, Sensory neuropathy, Seizures, Nystagmus, Disorder of eye, Pain, Dyspnea, Hypoxia, Pleural effusion (non-malignant), Pneumonitis/pulmonary infiltrates, Cystitis, Tumor lysis syndrome, Thrombosis and Embolism, other, Unterschrift
Randomisierter Vergleich zwischen Standard- und intensivierter Therapiestrategie der akuten myeloischen Leukämie des Erwachsenen im Alter von <= 60 Jahren Prospektive, randomisierte, multizentrische Therapieoptimierungsstudie - Studienprotokoll AML2003 http://www.clinicaltrials.gov/ct2/show/NCT00180102

Eligibility DRKS00003838 NCT00701766 Leukemia, Myeloid, Acute - Eligibility

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 21 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00701766

Eligibility NCT00682396 Myelodysplastic Syndrome - Eligibility

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 28 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00682396

Eligibility DRKS00002025 NCT00606723 Acute Myeloid Leukemia (AML) - Eligibility

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00606723

Eligibility DRKS00003742 NCT00632749 Leukemia, Myeloid, Acute - Eligibility

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 25 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00632749

1. Induction Acute Myeloid Leukemia <=60 years (AML2003) NCT00180102

- 20.09.21 - 1 Formulário, 7 Grupos de itens, 37 Elementos de dados, 2 Idiomas
Grupos de itens: General Info, Daunorubicin, Ara-C, G-CSF, Cytopenia duration, Transfusions, Signature
AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years http://clinicaltrials.gov/show/NCT00180102 Prospektive, randomisierte, multizentrische Therapieoptimierungsstudie - Studienprotokoll AML2003

Initial assessment Leukemia AML-AZA in elderly patients NCT00915252

- 20.09.21 - 1 Formulário, 10 Grupos de itens, 80 Elementos de dados, 2 Idiomas
Grupos de itens: Patient data, Clinical findings, Comorbidities, Differential blood count, Clinical Chemistry, Knochenmarkuntersuchung, Zytologie, FAB-Klassifikation, Molekulargenetik, Unterschrift
A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML NCT00915252

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial